Barclays’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $0 | Sell |
101
-16,939
| -99% | – | ﹤0.01% | 4501 |
|
|
2025
Q1 | $21K | Sell |
17,040
-6,840
| -29% | -$8.43K | ﹤0.01% | 4058 |
|
|
2024
Q4 | $45K | Buy |
23,880
+2,937
| +14% | +$5.54K | ﹤0.01% | 3972 |
|
|
2024
Q3 | $111K | Buy |
20,943
+18,249
| +677% | +$96.7K | ﹤0.01% | 3714 |
|
|
2024
Q2 | $20K | Sell |
2,694
-2,802
| -51% | -$20.8K | ﹤0.01% | 3900 |
|
|
2024
Q1 | $66K | Sell |
5,496
-5,299
| -49% | -$63.6K | ﹤0.01% | 3762 |
|
|
2023
Q4 | $85K | Buy |
10,795
+9,447
| +701% | +$74.4K | ﹤0.01% | 3748 |
|
|
2023
Q3 | $6K | Sell |
1,348
-200
| -13% | -$890 | ﹤0.01% | 4096 |
|
|
2023
Q2 | $54K | Sell |
1,548
-2,412
| -61% | -$84.1K | ﹤0.01% | 3644 |
|
|
2023
Q1 | $86K | Buy |
3,960
+2,370
| +149% | +$51.5K | ﹤0.01% | 3607 |
|
|
2022
Q4 | $34K | Buy |
1,590
+1,339
| +533% | +$28.6K | ﹤0.01% | 3900 |
|
|
2022
Q3 | $6K | Sell |
251
-46
| -15% | -$1.1K | ﹤0.01% | 4339 |
|
|
2022
Q2 | $6K | Sell |
297
-628
| -68% | -$12.7K | ﹤0.01% | 4442 |
|
|
2022
Q1 | $32K | Sell |
925
-4,480
| -83% | -$155K | ﹤0.01% | 4174 |
|
|
2021
Q4 | $147K | Buy |
5,405
+3,585
| +197% | +$97.5K | ﹤0.01% | 2893 |
|
|
2021
Q3 | $79K | Buy |
1,820
+969
| +114% | +$42.1K | ﹤0.01% | 3293 |
|
|
2021
Q2 | $42K | Buy |
851
+382
| +81% | +$18.9K | ﹤0.01% | 3461 |
|
|
2021
Q1 | $21K | Buy |
+469
| New | +$21K | ﹤0.01% | 3650 |
|
|
2020
Q2 | – | Sell |
-1,761
| Closed | -$21K | – | 3908 |
|
|
2020
Q1 | $21K | Hold |
1,761
| – | – | ﹤0.01% | 3372 |
|
|
2019
Q4 | $21K | Buy |
+1,761
| New | +$21K | ﹤0.01% | 3683 |
|
|
2019
Q2 | – | Sell |
-1
| Closed | – | – | 4350 |
|
|
2019
Q1 | $0 | Buy |
+1
| New | – | ﹤0.01% | 4363 |
|